{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T17:32:38Z","timestamp":1781026358490,"version":"3.54.1"},"reference-count":81,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,4,29]],"date-time":"2019-04-29T00:00:00Z","timestamp":1556496000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s12885-019-5558-8","type":"journal-article","created":{"date-parts":[[2019,4,29]],"date-time":"2019-04-29T13:29:58Z","timestamp":1556544598000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Plasma levels of M-CSF and VEGF in laboratory diagnostics and differentiation of selected histological types of cervical cancers"],"prefix":"10.1186","volume":"19","author":[{"given":"Iwona","family":"Sidorkiewicz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Zbucka-Kr\u0119towska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamil","family":"Zar\u0119ba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilia","family":"Lubowicka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Zajkowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maciej","family":"Szmitkowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ewa","family":"Gacuta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u0142awomir","family":"\u0141awicki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,4,29]]},"reference":[{"issue":"13","key":"5558_CR1","doi-asserted-by":"publisher","first-page":"2404","DOI":"10.1002\/cncr.30667","volume":"123","author":"W Small","year":"2017","unstructured":"Small W, Bacon MA, Bajaj A, Chuang LT, Fisher BJ, Harkenrider MM, et al. Cervical cancer: a global health crisis. Cancer. 2017;123(13):2404\u201312.","journal-title":"Cancer."},{"issue":"9","key":"5558_CR2","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1159\/000448385","volume":"39","author":"P Hillemanns","year":"2016","unstructured":"Hillemanns P, Soergel P, Hertel H, Jentschke M. Epidemiology and early detection of cervical Cancer. Oncol Res Treat. 2016;39(9):501\u20136.","journal-title":"Oncol Res Treat"},{"issue":"2","key":"5558_CR3","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.amepre.2015.01.009","volume":"49","author":"SM Carter","year":"2015","unstructured":"Carter SM, Williams J, Parker L, Pickles K, Jacklyn G, Rychetnik L, et al. Screening for cervical, prostate, and breast Cancer: interpreting the evidence. Am J Prev Med. 2015;49(2):274\u201385.","journal-title":"Am J Prev Med"},{"key":"5558_CR4","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1186\/1471-2407-12-491","volume":"12","author":"N Aminisani","year":"2012","unstructured":"Aminisani N, Armstrong BK, Egger S, Canfell K. Impact of organised cervical screening on cervical cancer incidence and mortality in migrant women in Australia. BMC Cancer. 2012;12:491.","journal-title":"BMC Cancer"},{"issue":"4","key":"5558_CR5","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.3892\/or.2013.2257","volume":"29","author":"JH Kim","year":"2013","unstructured":"Kim JH, Kim IW, Kim YW, Park DC, Lee KH, Ahn TG, et al. Comparison of single-, double- and triple-combined testing, including pap test, HPV DNA test and cervicography, as screening methods for the detection of uterine cervical cancer. Oncol Rep. 2013;29(4):1645\u201351.","journal-title":"Oncol Rep"},{"issue":"1","key":"5558_CR6","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1111\/cyt.12334","volume":"28","author":"A Herbert","year":"2017","unstructured":"Herbert A. Primary HPV testing: a proposal for co-testing in initial rounds of screening to optimise sensitivity of cervical cancer screening. Cytopathology. 2017;28(1):9\u201315.","journal-title":"Cytopathology."},{"key":"5558_CR7","doi-asserted-by":"crossref","unstructured":"C Kitchener H, Canfell K, Gilham C, Sargent A, Roberts C, Desai M, et al. The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds. Health Technol Assess 2014;18(23):1\u2013196.","DOI":"10.3310\/hta18230"},{"issue":"10","key":"5558_CR8","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1111\/1471-0528.12272","volume":"120","author":"M Zorzi","year":"2013","unstructured":"Zorzi M, Del Mistro A, Farruggio A, de'Bartolomeis L, Frayle-Salamanca H, Baboci L, et al. Use of a high-risk human papillomavirus DNA test as the primary test in a cervical cancer screening programme: a population-based cohort study. BJOG. 2013;120(10):1260\u20137; discussion 7-8.","journal-title":"BJOG."},{"key":"5558_CR9","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.cca.2015.03.005","volume":"445","author":"S Dasari","year":"2015","unstructured":"Dasari S, Wudayagiri R, Valluru L. Cervical cancer: biomarkers for diagnosis and treatment. Clin Chim Acta. 2015;445:7\u201311.","journal-title":"Clin Chim Acta"},{"issue":"2","key":"5558_CR10","doi-asserted-by":"publisher","first-page":"83","DOI":"10.14735\/amko201383","volume":"26","author":"L Moukov\u00e1","year":"2013","unstructured":"Moukov\u00e1 L, Nenutil R, Fabian P, Chovanec J. Prognostic factors for cervical cancer. Klin Onkol. 2013;26(2):83\u201390.","journal-title":"Klin Onkol"},{"issue":"6","key":"5558_CR11","first-page":"1075","volume":"68","author":"GL Perkins","year":"2003","unstructured":"Perkins GL, Slater ED, Sanders GK, Prichard JG. Serum tumor markers. Am Fam Physician. 2003;68(6):1075\u201382.","journal-title":"Am Fam Physician"},{"issue":"4","key":"5558_CR12","doi-asserted-by":"publisher","first-page":"744","DOI":"10.5306\/wjco.v5.i4.744","volume":"5","author":"SL McGraw","year":"2014","unstructured":"McGraw SL, Ferrante JM. Update on prevention and screening of cervical cancer. World J Clin Oncol. 2014;5(4):744\u201352.","journal-title":"World J Clin Oncol"},{"key":"5558_CR13","doi-asserted-by":"crossref","unstructured":"Valenti G, Vitale SG, Tropea A, Biondi A, Lagan\u00e0 AS. Tumor markers of uterine cervical cancer: a new scenario to guide surgical practice? Updat Surg. 2017.","DOI":"10.1007\/s13304-017-0491-3"},{"key":"5558_CR14","doi-asserted-by":"publisher","first-page":"600","DOI":"10.3332\/ecancer.2015.600","volume":"9","author":"A Albini","year":"2015","unstructured":"Albini A, Bertolini F, Bassani B, Bruno A, Gallo C, Caraffi SG, et al. Biomarkers of cancer angioprevention for clinical studies. Ecancermedicalscience. 2015;9:600.","journal-title":"Ecancermedicalscience."},{"key":"5558_CR15","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/274726","volume":"2013","author":"K Semeran","year":"2013","unstructured":"Semeran K, Paw\u0142owski P, Lisowski \u0141, Szczepaniak I, W\u00f3jtowicz J, \u0141awicki S, et al. Plasma levels of IL-17, VEGF, and adrenomedullin and S-cone dysfunction of the retina in children and adolescents without signs of retinopathy and with varied duration of diabetes. Mediat Inflamm. 2013;2013:274726.","journal-title":"Mediat Inflamm"},{"issue":"6","key":"5558_CR16","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1038\/nm0603-669","volume":"9","author":"N Ferrara","year":"2003","unstructured":"Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med. 2003;9(6):669\u201376.","journal-title":"Nat Med"},{"issue":"5","key":"5558_CR17","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.3892\/ijo.2016.3709","volume":"49","author":"E Maj","year":"2016","unstructured":"Maj E, Papiernik D, Wietrzyk J. Antiangiogenic cancer treatment: the great discovery and greater complexity (review). Int J Oncol. 2016;49(5):1773\u201384.","journal-title":"Int J Oncol"},{"issue":"3","key":"5558_CR18","doi-asserted-by":"publisher","first-page":"298","DOI":"10.2174\/1574892810999150827153642","volume":"10","author":"DR Abdalla","year":"2015","unstructured":"Abdalla DR, Simoens C, Bogers JP, Murta EF, Michelin MA. Angiogenesis markers in gynecological tumors and patents for anti-Angiogenic approach: review. Recent Pat Anticancer Drug Discov. 2015;10(3):298\u2013307.","journal-title":"Recent Pat Anticancer Drug Discov"},{"issue":"12","key":"5558_CR19","doi-asserted-by":"publisher","first-page":"9285","DOI":"10.1007\/s13277-015-3663-0","volume":"36","author":"D P\u00e9rez","year":"2015","unstructured":"P\u00e9rez D, Rohde A, Callej\u00f3n G, P\u00e9rez-Ruiz E, Rodrigo I, Rivas-Ruiz F, et al. Correlation between serum levels of vascular endothelial growth factor-C and sentinel lymph node status in early breast cancer. Tumour Biol. 2015;36(12):9285\u201393.","journal-title":"Tumour Biol"},{"issue":"6","key":"5558_CR20","doi-asserted-by":"publisher","first-page":"3937","DOI":"10.7314\/APJCP.2013.14.6.3937","volume":"14","author":"SJ Zhang","year":"2013","unstructured":"Zhang SJ, Hu Y, Qian HL, Jiao SC, Liu ZF, Tao HT, et al. Expression and significance of ER, PR, VEGF, CA15-3, CA125 and CEA in judging the prognosis of breast cancer. Asian Pac J Cancer Prev. 2013;14(6):3937\u201340.","journal-title":"Asian Pac J Cancer Prev"},{"issue":"1","key":"5558_CR21","doi-asserted-by":"publisher","first-page":"175","DOI":"10.3892\/etm.2014.1685","volume":"8","author":"J Zhang","year":"2014","unstructured":"Zhang J, Yin L, Wu J, Zhang Y, Xu T, Ma R, et al. Detection of serum VEGF and MMP-9 levels by Luminex multiplexed assays in patients with breast infiltrative ductal carcinoma. Exp Ther Med. 2014;8(1):175\u201380.","journal-title":"Exp Ther Med"},{"issue":"1","key":"5558_CR22","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1684\/ecn.2011.0276","volume":"22","author":"B Dobrzycka","year":"2011","unstructured":"Dobrzycka B, Terlikowski SJ, Kowalczuk O, Kulikowski M, Niklinski J. Serum levels of VEGF and VEGF-C in patients with endometrial cancer. Eur Cytokine Netw. 2011;22(1):45\u201351.","journal-title":"Eur Cytokine Netw"},{"key":"5558_CR23","doi-asserted-by":"publisher","first-page":"243298","DOI":"10.1155\/2015\/243298","volume":"2015","author":"T Cuppens","year":"2015","unstructured":"Cuppens T, Tuyaerts S, Amant F. Potential therapeutic targets in uterine sarcomas. Sarcoma. 2015;2015:243298.","journal-title":"Sarcoma."},{"issue":"8","key":"5558_CR24","first-page":"649","volume":"75","author":"M Zbucka","year":"2004","unstructured":"Zbucka M, Koda M, Tomaszewski J, Przystupa W, Sulkowski S, Wo\u0142czy\u0144ski S. Angiogenesis in the female reproductive processes. Ginekol Pol. 2004;75(8):649\u201357.","journal-title":"Ginekol Pol"},{"issue":"2","key":"5558_CR25","doi-asserted-by":"publisher","first-page":"e55309","DOI":"10.1371\/journal.pone.0055309","volume":"8","author":"D Cheng","year":"2013","unstructured":"Cheng D, Liang B, Li Y. Serum vascular endothelial growth factor (VEGF-C) as a diagnostic and prognostic marker in patients with ovarian cancer. PLoS One. 2013;8(2):e55309.","journal-title":"PLoS One"},{"issue":"4","key":"5558_CR26","doi-asserted-by":"publisher","first-page":"309","DOI":"10.3109\/00365513.2013.773593","volume":"73","author":"B Liang","year":"2013","unstructured":"Liang B, Guo Z, Li Y, Liu C. Elevated VEGF concentrations in ascites and serum predict adverse prognosis in ovarian cancer. Scand J Clin Lab Invest. 2013;73(4):309\u201314.","journal-title":"Scand J Clin Lab Invest"},{"issue":"3","key":"5558_CR27","first-page":"870","volume":"20","author":"G Hui","year":"2015","unstructured":"Hui G, Meng M. Prognostic value of vascular endothelial growth factor expression in women with ovarian cancer: a meta-analysis. J BUON. 2015;20(3):870\u20138.","journal-title":"J BUON"},{"issue":"5","key":"5558_CR28","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1016\/j.apsb.2015.07.005","volume":"5","author":"X Guan","year":"2015","unstructured":"Guan X. Cancer metastases: challenges and opportunities. Acta Pharm Sin B. 2015;5(5):402\u201318.","journal-title":"Acta Pharm Sin B"},{"key":"5558_CR29","doi-asserted-by":"publisher","first-page":"489","DOI":"10.3389\/fimmu.2014.00489","volume":"5","author":"D Laoui","year":"2014","unstructured":"Laoui D, Van Overmeire E, De Baetselier P, Van Ginderachter JA, Raes G. Functional Relationship between Tumor-Associated Macrophages and Macrophage Colony-Stimulating Factor as Contributors to Cancer Progression. Front Immunol. 2014;5:489.","journal-title":"Front Immunol"},{"issue":"6","key":"5558_CR30","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1016\/j.ccr.2014.05.016","volume":"25","author":"CH Ries","year":"2014","unstructured":"Ries CH, Cannarile MA, Hoves S, Benz J, Wartha K, Runza V, et al. Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy. Cancer Cell. 2014;25(6):846\u201359.","journal-title":"Cancer Cell"},{"issue":"1","key":"5558_CR31","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1158\/0008-5472.CAN-15-0869","volume":"76","author":"E Overmeire Van","year":"2016","unstructured":"Van Overmeire E, Stijlemans B, Heymann F, Keirsse J, Morias Y, Elkrim Y, et al. M-CSF and GM-CSF receptor signaling differentially regulate monocyte maturation and macrophage polarization in the tumor microenvironment. Cancer Res. 2016;76(1):35\u201342.","journal-title":"Cancer Res"},{"issue":"2","key":"5558_CR32","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.ijgo.2014.02.003","volume":"125","author":"Oncology FCoG","year":"2014","unstructured":"Oncology FCoG. FIGO staging for carcinoma of the vulva, cervix, and corpus uteri. Int J Gynaecol Obstet. 2014;125(2):97\u20138.","journal-title":"Int J Gynaecol Obstet"},{"issue":"1","key":"5558_CR33","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1097\/PGP.0b013e31826916c7","volume":"32","author":"TM Darragh","year":"2013","unstructured":"Darragh TM, Colgan TJ, Thomas Cox J, Heller DS, Henry MR, Luff RD, et al. The lower Anogenital squamous terminology standardization project for HPV-associated lesions: background and consensus recommendations from the College of American Pathologists and the American Society for Colposcopy and Cervical Pathology. Int J Gynecol Pathol. 2013;32(1):76\u2013115.","journal-title":"Int J Gynecol Pathol"},{"key":"5558_CR34","doi-asserted-by":"crossref","unstructured":"Lubowicka E, Zbucka-Kretowska M, Sidorkiewicz I, Zajkowska M, Gacuta E, Puchnarewicz A, et al. Diagnostic power of cytokine M-CSF, metalloproteinase 2 (MMP-2) and tissue Inhibitor-2 (TIMP-2) in cervical Cancer patients based on ROC analysis. Pathol Oncol Res. 2019.","DOI":"10.1007\/s12253-019-00626-z"},{"issue":"7","key":"5558_CR35","doi-asserted-by":"publisher","first-page":"101042831879036","DOI":"10.1177\/1010428318790363","volume":"40","author":"Monika Zajkowska","year":"2018","unstructured":"Zajkowska M, Zbucka-Kr\u0119towska M, Sidorkiewicz I, Lubowicka E, Gacuta E, Szmitkowski M, et al. Plasma levels and diagnostic utility of macrophage-colony stimulating factor, matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 as tumor markers in cervical cancer patients. Tumour Biol 2018;40(7):1010428318790363.","journal-title":"Tumor Biology"},{"issue":"1","key":"5558_CR36","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1080\/03610929108830487","volume":"20","author":"CE Douglas","year":"1991","unstructured":"Douglas CE, Michael FA. On distribution-free multiple comparisons in the one-way analysis of variance. Communications in Statistics - Theory and Methods. 1991;20(1):127\u201339.","journal-title":"Communications in Statistics - Theory and Methods"},{"issue":"1","key":"5558_CR37","doi-asserted-by":"publisher","first-page":"8","DOI":"10.4097\/kjae.2016.69.1.8","volume":"69","author":"FS Nahm","year":"2016","unstructured":"Nahm FS. Nonparametric statistical tests for the continuous data: the basic concept and the practical use. Korean J Anesthesiol. 2016;69(1):8\u201314.","journal-title":"Korean J Anesthesiol"},{"issue":"4","key":"5558_CR38","first-page":"203","volume":"19","author":"AM \u0160imundi\u0107","year":"2009","unstructured":"\u0160imundi\u0107 AM. Measures of diagnostic accuracy: basic definitions. EJIFCC. 2009;19(4):203\u201311.","journal-title":"EJIFCC."},{"issue":"1","key":"5558_CR39","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.maturitas.2010.04.017","volume":"67","author":"P Aggarwal","year":"2010","unstructured":"Aggarwal P, Kehoe S. Serum tumour markers in gynaecological cancers. Maturitas. 2010;67(1):46\u201353.","journal-title":"Maturitas."},{"issue":"6","key":"5558_CR40","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1159\/000030143","volume":"21","author":"T Tabata","year":"2000","unstructured":"Tabata T, Takeshima N, Tanaka N, Hirai Y, Hasumi K. Clinical value of tumor markers for early detection of recurrence in patients with cervical adenocarcinoma and adenosquamous carcinoma. Tumour Biol. 2000;21(6):375\u201380.","journal-title":"Tumour Biol"},{"issue":"4","key":"5558_CR41","doi-asserted-by":"publisher","first-page":"689","DOI":"10.4103\/jcrt.JCRT_414_17","volume":"13","author":"S Guo","year":"2017","unstructured":"Guo S, Yang B, Liu H, Li Y, Li S, Ma L, et al. Serum expression level of squamous cell carcinoma antigen, highly sensitive C-reactive protein, and CA-125 as potential biomarkers for recurrence of cervical cancer. J Cancer Res Ther. 2017;13(4):689\u201392.","journal-title":"J Cancer Res Ther"},{"issue":"2","key":"5558_CR42","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1007\/s00432-008-0442-y","volume":"135","author":"PL Zusterzeel","year":"2009","unstructured":"Zusterzeel PL, Span PN, Dijksterhuis MG, Thomas CM, Sweep FC, Massuger LF. Serum vascular endothelial growth factor: a prognostic factor in cervical cancer. J Cancer Res Clin Oncol. 2009;135(2):283\u201390.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"4","key":"5558_CR43","first-page":"144","volume":"3","author":"S Srivastava","year":"2009","unstructured":"Srivastava S, Gupta A, Agarwal GG, Natu SM, Uma S, Goel MM, et al. Correlation of serum vascular endothelial growth factor with clinicopathological parameters in cervical cancer. Biosci Trends. 2009;3(4):144\u201350.","journal-title":"Biosci Trends"},{"issue":"20","key":"5558_CR44","doi-asserted-by":"publisher","first-page":"8793","DOI":"10.7314\/APJCP.2014.15.20.8793","volume":"15","author":"K Du","year":"2014","unstructured":"Du K, Gong HY, Gong ZM. Influence of serum VEGF levels on therapeutic outcome and diagnosis\/prognostic value in patients with cervical cancer. Asian Pac J Cancer Prev. 2014;15(20):8793\u20136.","journal-title":"Asian Pac J Cancer Prev"},{"issue":"3","key":"5558_CR45","first-page":"699","volume":"12","author":"K Katanyoo","year":"2011","unstructured":"Katanyoo K, Chantarasri A, Chongtanakon M, Rongsriyam K, Tantivatana T. Pretreatment levels of serum vascular endothelial growth factor do not correlate with outcome in patients with locally advanced cervical cancer. Asian Pac J Cancer Prev. 2011;12(3):699\u2013702.","journal-title":"Asian Pac J Cancer Prev"},{"key":"5558_CR46","volume":"2016","author":"L Wang","year":"2016","unstructured":"Wang L, Chang Y, Xu J, Zhang Q. Predictive significance of serum level of vascular endothelial growth factor in gastric Cancer patients. Biomed Res Int. 2016;2016:8103019.","journal-title":"Biomed Res Int"},{"issue":"3","key":"5558_CR47","first-page":"1013","volume":"33","author":"T Mukozu","year":"2013","unstructured":"Mukozu T, Nagai H, Matsui D, Kanekawa T, Sumino Y. Serum VEGF as a tumor marker in patients with HCV-related liver cirrhosis and hepatocellular carcinoma. Anticancer Res. 2013;33(3):1013\u201321.","journal-title":"Anticancer Res"},{"issue":"9","key":"5558_CR48","first-page":"4867","volume":"37","author":"R Divella","year":"2017","unstructured":"Divella R, Daniele A, DE Luca R, Simone M, Naglieri E, Savino E, et al. Circulating levels of VEGF and CXCL1 are predictive of metastatic Organotropismin in patients with colorectal Cancer. Anticancer Res. 2017;37(9):4867\u201371.","journal-title":"Anticancer Res"},{"key":"5558_CR49","doi-asserted-by":"publisher","first-page":"36065","DOI":"10.1038\/srep36065","volume":"6","author":"MM Balla","year":"2016","unstructured":"Balla MM, Desai S, Purwar P, Kumar A, Bhandarkar P, Shejul YK, et al. Differential diagnosis of lung cancer, its metastasis and chronic obstructive pulmonary disease based on serum Vegf, Il-8 and MMP-9. Sci Rep. 2016;6:36065.","journal-title":"Sci Rep"},{"issue":"5","key":"5558_CR50","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1097\/CEJ.0b013e32833b48e1","volume":"19","author":"F Botelho","year":"2010","unstructured":"Botelho F, Pina F, Lunet N. VEGF and prostatic cancer: a systematic review. Eur J Cancer Prev. 2010;19(5):385\u201392.","journal-title":"Eur J Cancer Prev"},{"issue":"3","key":"5558_CR51","doi-asserted-by":"publisher","first-page":"e14778","DOI":"10.5812\/numonthly.14778","volume":"6","author":"MR Sharif","year":"2014","unstructured":"Sharif MR, Shaabani A, Mahmoudi H, Nikoueinejad H, Akbari H, Einollahi B. Association of the serum vascular endothelial growth factor levels with benign prostate hyperplasia and prostate malignancies. Nephrourol Mon. 2014;6(3):e14778.","journal-title":"Nephrourol Mon"},{"key":"5558_CR52","doi-asserted-by":"publisher","first-page":"5962946","DOI":"10.1155\/2016\/5962946","volume":"2016","author":"M Zajkowska","year":"2016","unstructured":"Zajkowska M, G\u0142a\u017cewska EK, B\u0119dkowska GE, Chor\u0105\u017cy P, Szmitkowski M, \u0141awicki S. Diagnostic power of vascular endothelial growth factor and macrophage Colony-stimulating factor in breast Cancer patients based on ROC analysis. Mediat Inflamm. 2016;2016:5962946.","journal-title":"Mediat Inflamm"},{"key":"5558_CR53","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s13048-015-0153-3","volume":"8","author":"GE B\u0119dkowska","year":"2015","unstructured":"B\u0119dkowska GE, \u0141awicki S, Gacuta E, Paw\u0142owski P, Szmitkowski M. M-CSF in a new biomarker panel with HE4 and CA 125 in the diagnostics of epithelial ovarian cancer patients. J Ovarian Res. 2015;8:27.","journal-title":"J Ovarian Res"},{"issue":"6","key":"5558_CR54","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1097\/IGC.0000000000001006","volume":"27","author":"B Gonz\u00e1lez-Palomares","year":"2017","unstructured":"Gonz\u00e1lez-Palomares B, Coronado Mart\u00edn PJ, Maestro de Las Casas ML, Veganzones de Castro S, Rafael Fern\u00e1ndez S, Vidaurreta L\u00e1zaro M, et al. Vascular endothelial growth factor (VEGF) polymorphisms and serum VEGF levels in women with epithelial ovarian Cancer, benign tumors, and healthy ovaries. Int J Gynecol Cancer. 2017;27(6):1088\u201395.","journal-title":"Int J Gynecol Cancer"},{"issue":"20","key":"5558_CR55","doi-asserted-by":"publisher","first-page":"4059","DOI":"10.1200\/JCO.2004.03.091","volume":"22","author":"SJ Skates","year":"2004","unstructured":"Skates SJ, Horick N, Yu Y, Xu FJ, Berchuck A, Havrilesky LJ, et al. Preoperative sensitivity and specificity for early-stage ovarian cancer when combining cancer antigen CA-125II, CA 15-3, CA 72-4, and macrophage colony-stimulating factor using mixtures of multivariate normal distributions. J Clin Oncol. 2004;22(20):4059\u201366.","journal-title":"J Clin Oncol"},{"issue":"156","key":"5558_CR56","first-page":"609","volume":"26","author":"S \u0141awicki","year":"2009","unstructured":"\u0141awicki S, Bedkowska GE, Gacuta-Szumarska E, Czygier M, Szmitkowski M. The plasma levels and diagnostic utility of stem cell factor in patients with endometrial cancer and myoma uteri. Pol Merkur Lekarski. 2009;26(156):609\u201315.","journal-title":"Pol Merkur Lekarski"},{"issue":"9","key":"5558_CR57","first-page":"1661","volume":"62","author":"S \u0141awicki","year":"2016","unstructured":"\u0141awicki S, Zajkowska M, G\u0142a\u017cewska EK, B\u0119dkowska GE, Szmitkowski M. Plasma levels and diagnostic utility of M-CSF, MMP-2 and its inhibitor TIMP-2 in the diagnostics of breast Cancer patients. Clin Lab. 2016;62(9):1661\u20139.","journal-title":"Clin Lab"},{"issue":"6","key":"5558_CR58","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1530\/ERC-13-0198","volume":"20","author":"S Aharinejad","year":"2013","unstructured":"Aharinejad S, Salama M, Paulus P, Zins K, Berger A, Singer CF. Elevated CSF1 serum concentration predicts poor overall survival in women with early breast cancer. Endocr Relat Cancer. 2013;20(6):777\u201383.","journal-title":"Endocr Relat Cancer"},{"issue":"2","key":"5558_CR59","doi-asserted-by":"publisher","first-page":"207","DOI":"10.2478\/ams-2013-0023","volume":"58","author":"S \u0141awicki","year":"2013","unstructured":"\u0141awicki S, B\u0119dkowska GE, Wojtukiewicz M, Szmitkowski M. Hematopoietic cytokines as tumor markers in breast malignancies. A multivariate analysis with ROC curve in breast cancer patients. Adv Med Sci. 2013;58(2):207\u201315.","journal-title":"Adv Med Sci"},{"issue":"2","key":"5558_CR60","doi-asserted-by":"publisher","first-page":"213","DOI":"10.5603\/FHC.2012.0030","volume":"50","author":"S \u0141awicki","year":"2012","unstructured":"\u0141awicki S, B\u0119dkowska GE, Gacuta-Szumarska E, Knapp P, Szmitkowski M. Pretreatment plasma levels and diagnostic utility of hematopoietic cytokines in cervical cancer or cervical intraepithelial neoplasia patients. Folia Histochem Cytobiol. 2012;50(2):213\u20139.","journal-title":"Folia Histochem Cytobiol"},{"issue":"6","key":"5558_CR61","first-page":"1745","volume":"11","author":"M Porika","year":"2010","unstructured":"Porika M, Vemunoori AK, Tippani R, Mohammad A, Bollam SR, Abbagani S. Squamous cell carcinoma antigen and cancer antigen 125 in southern Indian cervical cancer patients. Asian Pac J Cancer Prev. 2010;11(6):1745\u20137.","journal-title":"Asian Pac J Cancer Prev"},{"issue":"8","key":"5558_CR62","doi-asserted-by":"publisher","first-page":"1830","DOI":"10.1002\/1097-0142(19900415)65:8<1830::AID-CNCR2820650828>3.0.CO;2-S","volume":"65","author":"JM Duk","year":"1990","unstructured":"Duk JM, De Bruijn HW, Groenier KH, Fleuren GJ, Aalders JG. Adenocarcinoma of the uterine cervix. Prognostic significance of pretreatment serum CA 125, squamous cell carcinoma antigen, and carcinoembryonic antigen levels in relation to clinical and histopathologic tumor characteristics. Cancer. 1990;65(8):1830\u20137.","journal-title":"Cancer."},{"issue":"1","key":"5558_CR63","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1067\/mob.2003.443","volume":"189","author":"DP Bender","year":"2003","unstructured":"Bender DP, Sorosky JI, Buller RE, Sood AK. Serum CA 125 is an independent prognostic factor in cervical adenocarcinoma. Am J Obstet Gynecol. 2003;189(1):113\u20137.","journal-title":"Am J Obstet Gynecol"},{"issue":"4","key":"5558_CR64","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1111\/IGC.0b013e3181d5c27a","volume":"20","author":"B Kotowicz","year":"2010","unstructured":"Kotowicz B, Kaminska J, Fuksiewicz M, Kowalska M, Jonska-Gmyrek J, Gawrychowski K, et al. Clinical significance of serum CA-125 and soluble tumor necrosis factor receptor type I in cervical adenocarcinoma patients. Int J Gynecol Cancer. 2010;20(4):588\u201392.","journal-title":"Int J Gynecol Cancer"},{"issue":"6","key":"5558_CR65","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1159\/000030044","volume":"19","author":"HW Bruijn de","year":"1998","unstructured":"de Bruijn HW, Duk JM, van der Zee AG, Pras E, Willemse PH, Boonstra H, et al. The clinical value of squamous cell carcinoma antigen in cancer of the uterine cervix. Tumour Biol. 1998;19(6):505\u201316.","journal-title":"Tumour Biol"},{"issue":"1","key":"5558_CR66","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.ygyno.2008.09.042","volume":"112","author":"J Lande van de","year":"2009","unstructured":"van de Lande J, Davelaar EM, von Mensdorff-Pouilly S, Water TJ, Berkhof J, van Baal WM, et al. SCC-ag, lymph node metastases and sentinel node procedure in early stage squamous cell cervical cancer. Gynecol Oncol. 2009;112(1):119\u201325.","journal-title":"Gynecol Oncol"},{"issue":"1","key":"5558_CR67","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.ygyno.2016.04.029","volume":"142","author":"M Salvatici","year":"2016","unstructured":"Salvatici M, Achilarre MT, Sandri MT, Boveri S, Vanna Z, Landoni F. Squamous cell carcinoma antigen (SCC-ag) during follow-up of cervical cancer patients: role in the early diagnosis of recurrence. Gynecol Oncol. 2016;142(1):115\u20139.","journal-title":"Gynecol Oncol"},{"issue":"1","key":"5558_CR68","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1007\/s13277-015-3914-0","volume":"37","author":"B Kotowicz","year":"2016","unstructured":"Kotowicz B, Fuksiewicz M, Jonska-Gmyrek J, Bidzinski M, Kowalska M. The assessment of the prognostic value of tumor markers and cytokines as SCCAg, CYFRA 21.1, IL-6, VEGF and sTNF receptors in patients with squamous cell cervical cancer, particularly with early stage of the disease. Tumour Biol. 2016;37(1):1271\u20138.","journal-title":"Tumour Biol"},{"issue":"3","key":"5558_CR69","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1006\/gyno.2000.5784","volume":"77","author":"M Suzuki","year":"2000","unstructured":"Suzuki M, Tamura N, Kobayashi H, Ohwada M, Terao T, Sato I. Clinical significance of combined use of macrophage colony-stimulating factor and squamous cell carcinoma antigen as a selective diagnostic marker for squamous cell carcinoma arising in mature cystic teratoma of the ovary. Gynecol Oncol. 2000;77(3):405\u20139.","journal-title":"Gynecol Oncol"},{"issue":"1","key":"5558_CR70","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1006\/gyno.2001.6517","volume":"85","author":"A Lebrecht","year":"2002","unstructured":"Lebrecht A, Ludwig E, Huber A, Klein M, Schneeberger C, Tempfer C, et al. Serum vascular endothelial growth factor and serum leptin in patients with cervical cancer. Gynecol Oncol. 2002;85(1):32\u20135.","journal-title":"Gynecol Oncol"},{"issue":"5","key":"5558_CR71","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1034\/j.1600-0412.2002.810513.x","volume":"81","author":"M Takeda","year":"2002","unstructured":"Takeda M, Sakuragi N, Okamoto K, Todo Y, Minobe S, Nomura E, et al. Preoperative serum SCC, CA125, and CA19-9 levels and lymph node status in squamous cell carcinoma of the uterine cervix. Acta Obstet Gynecol Scand. 2002;81(5):451\u20137.","journal-title":"Acta Obstet Gynecol Scand"},{"key":"5558_CR72","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/j.cca.2013.07.003","volume":"424","author":"J Li","year":"2013","unstructured":"Li J, Cheng H, Zhang P, Dong Z, Tong HL, Han JD, et al. Prognostic value of combined serum biomarkers in predicting outcomes in cervical cancer patients. Clin Chim Acta. 2013;424:292\u20137.","journal-title":"Clin Chim Acta"},{"issue":"25","key":"5558_CR73","doi-asserted-by":"publisher","first-page":"3044","DOI":"10.1200\/JCO.2011.38.8389","volume":"30","author":"PE Castle","year":"2012","unstructured":"Castle PE, Glass AG, Rush BB, Scott DR, Wentzensen N, Gage JC, et al. Clinical human papillomavirus detection forecasts cervical cancer risk in women over 18 years of follow-up. J Clin Oncol. 2012;30(25):3044\u201350.","journal-title":"J Clin Oncol"},{"key":"5558_CR74","doi-asserted-by":"crossref","unstructured":"Nkwabong E, Laure Bessi Badjan I, Sando Z. Pap smear accuracy for the diagnosis of cervical precancerous lesions. Trop Dr 2018:49475518798532.","DOI":"10.1177\/0049475518798532"},{"issue":"11","key":"5558_CR75","doi-asserted-by":"publisher","first-page":"3033","DOI":"10.1158\/1055-9965.EPI-08-0508","volume":"17","author":"A Szarewski","year":"2008","unstructured":"Szarewski A, Ambroisine L, Cadman L, Austin J, Ho L, Terry G, et al. Comparison of predictors for high-grade cervical intraepithelial neoplasia in women with abnormal smears. Cancer Epidemiol Biomark Prev. 2008;17(11):3033\u201342.","journal-title":"Cancer Epidemiol Biomark Prev"},{"issue":"8","key":"5558_CR76","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0024083","volume":"6","author":"SW S\u00f8rbye","year":"2011","unstructured":"S\u00f8rbye SW, Arbyn M, Fismen S, Gutteberg TJ, Mortensen ES. Triage of women with low-grade cervical lesions--HPV mRNA testing versus repeat cytology. PLoS One. 2011;6(8):e24083.","journal-title":"PLoS One"},{"key":"5558_CR77","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s12907-017-0058-8","volume":"17","author":"SW S\u00f8rbye","year":"2017","unstructured":"S\u00f8rbye SW, Suhrke P, Rev\u00e5 BW, Berland J, Maurseth RJ, Al-Shibli K. Accuracy of cervical cytology: comparison of diagnoses of 100 pap smears read by four pathologists at three hospitals in Norway. BMC Clin Pathol. 2017;17:18.","journal-title":"BMC Clin Pathol"},{"issue":"8","key":"5558_CR78","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0161403","volume":"11","author":"M Castillo","year":"2016","unstructured":"Castillo M, Astudillo A, Clavero O, Velasco J, Ib\u00e1\u00f1ez R, de Sanjos\u00e9 S. Poor cervical Cancer screening attendance and false negatives. A call for organized screening. PLoS One. 2016;11(8):e0161403.","journal-title":"PLoS One"},{"issue":"1","key":"5558_CR79","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1111\/j.1365-2303.2011.00948.x","volume":"23","author":"A Castanon","year":"2012","unstructured":"Castanon A, Ferryman S, Patnick J, Sasieni P. Review of cytology and histopathology as part of the NHS cervical screening Programme audit of invasive cervical cancers. Cytopathology. 2012;23(1):13\u201322.","journal-title":"Cytopathology."},{"issue":"2","key":"5558_CR80","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1007\/s12250-015-3586-3","volume":"30","author":"L Jin","year":"2015","unstructured":"Jin L, Xu ZX. Recent advances in the study of HPV-associated carcinogenesis. Virol Sin. 2015;30(2):101\u20136.","journal-title":"Virol Sin"},{"key":"5558_CR81","doi-asserted-by":"crossref","unstructured":"Siveen KS, Prabhu K, Krishnankutty R, Kuttikrishnan S, Tsakou M, Alali FQ, et al. Vascular endothelial growth factor (VEGF) signaling in tumour vascularization: potential and challenges. Curr Vasc Pharmacol. 2017.","DOI":"10.2174\/1570161115666170105124038"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-019-5558-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12885-019-5558-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-019-5558-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,27]],"date-time":"2020-04-27T23:10:31Z","timestamp":1588029031000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-019-5558-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,29]]},"references-count":81,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["5558"],"URL":"https:\/\/doi.org\/10.1186\/s12885-019-5558-8","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4,29]]},"assertion":[{"value":"3 January 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All procedures performed in the studies involving human participants were in accordance with the ethical standard of the ethical committee at Medical University of Bialystok (R-I-002\/239\/2014) and written informed consent was obtained from each patient for research purposes.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"398"}}